Latanoprost or brimonidine as treatment for elevated intraocular pressure: Multicenter trial in the United States

Journal of Glaucoma

Volumn 14, Issue 2, 2005, Pages 161-167

  Camras, Carl B ^a,c,d   Sheu, Wang Pui ^b,d  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^b Pfizer Ltd   (United States)

^c PFIZER INC   (United States)

^d Pharmacia Statistical Operations ^*  (United States)

Author keywords

Brimonidine; Efficacy; Latanoprost; Ocular hypertension; Primary open angle glaucoma

Indexed keywords

ALPHA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BRIMONIDINE; CARBONATE DEHYDRATASE INHIBITOR; CHOLINERGIC RECEPTOR STIMULATING AGENT; DORZOLAMIDE; LATANOPROST; PILOCARPINE; PROSTAGLANDIN F2 ALPHA DERIVATIVE; TIMOLOL;

ADULT; AGED; ALLERGIC CONJUNCTIVITIS; ARTICLE; CATARACT; CENTRAL NERVOUS SYSTEM DISEASE; CIRCADIAN RHYTHM; CLINICAL TRIAL; CONJUNCTIVA DISEASE; CONJUNCTIVITIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DERMATITIS; DIPLOPIA; DIZZINESS; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG TOLERABILITY; EYE IRRITATION; EYE PAIN; EYELID DISEASE; EYELID EDEMA; FACE EDEMA; FATIGUE; FEMALE; FOLLOW UP; HEADACHE; HEART PALPITATION; HUMAN; INTRAOCULAR HYPERTENSION; INTRAOCULAR PRESSURE; LACRIMATION; LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; MULTICENTER STUDY; OPEN ANGLE GLAUCOMA; OUTCOMES RESEARCH; PRESSURE MEASUREMENT; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SINUSITIS; SOMNOLENCE; UNITED STATES; VISUAL ACUITY; VISUAL IMPAIRMENT; XEROSTOMIA;

ADULT; AGED; AGED, 80 AND OVER; ANTIHYPERTENSIVE AGENTS; DOUBLE-BLIND METHOD; FEMALE; GLAUCOMA, OPEN-ANGLE; HUMANS; INTRAOCULAR PRESSURE; MALE; MIDDLE AGED; OCULAR HYPERTENSION; PROSPECTIVE STUDIES; PROSTAGLANDINS F, SYNTHETIC; QUINOXALINES; SAFETY; TONOMETRY, OCULAR; TREATMENT OUTCOME; UNITED STATES;

EID: 15244359848     PISSN: 10570829     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.ijg.0000151881.99607.4e     Document Type: Article

References (31)

1. Alm A, Stjernschantz J, for the Scandinavian Latanoprost Study Group. Effects on intraocular pressure and side effects of 0.005% latanoprost applied once daily, evening or morning. A comparison with timolol. Ophthalmology. 1995;102:1743-1752.
2. Camras CB, for the United States Latanoprost Study Group. Comparison of latanoprost and timolol in patients with ocular hypertension and glaucoma. A six-month, masked, multicenter trial in the United States. Ophthalmology. 1996;103:138-147.
3. Mishima HK, Masuda K, Kitazawa Y, et al. A comparison of latanoprost and timolol in primary open-angle glaucoma and ocular hypertension. A 12-week study. Arch Ophthalmol. 1996;114:929-932.
4. Watson P, Stjernschantz J, for the Latanoprost Study Group. A six-month, randomized, double-masked study comparing latanoprost with timolol in open-angle glaucoma and ocular hypertension. Ophthalmology. 1996;103: 126-137.
5. Katz LJ. Brimonidine tartrate 0.2% twice daily vs timolol 0.5% twice daily: 1-year results in glaucoma patients. Am J Ophthalmol. 1999;127: 20-26.
6. LeBlanc RP. Twelve-month results of an ongoing randomized trial comparing brimonidine tartrate 0.2% and timolol 0.5% given twice daily in patients with glaucoma or ocular hypertension. Ophthalmology. 1998; 105:1960-1967.
7. Schuman JS. Clinical experience with brimonidine 0.2% and timolol 0.5% in glaucoma and ocular hypertension. Surv Ophthalmol. 1996;41 (Suppl 1): S27-S37.
8. Schuman JS, Horwitz B, Choplin NT, et al. A 1-year study of brimonidine twice daily in glaucoma and ocular hypertension. A controlled, randomized, multicenter clinical trial. Arch Ophthalmol. 1997;115:847-852.
9. 2-alpha analog, on aqueous humor dynamics in human eyes. Ophthalmology. 1993;100:1297-1304.
10. Toris CB, Gleason ML, Camras CB, et al. Effects of brimonidine on aqueous humor dynamics in human eyes. Arch Ophthalmol. 1995;113: 1514-1517.
11. Toris CB, Camras CB, Yablonski ME. Acute versus chronic effects of brimonidine on aqueous humor dynamics in ocular hypertensive patients. Am J Ophthalmol. 1999;128:8-14.
12. 2-alpha analogue, after topical application in normal and ocular hypertensive human eyes. Arch Ophthalmol. 1993; 111:1351-1358.
13. Einarson TR, Kulin NA, Tingey D, et al. Meta-analysis of the effect of latanoprost and brimonidine on intraocular pressure in the treatment of glaucoma. Clin Ther. 2000;22:1502-1515.
14. Stewart WC, Day DG, Stewart JA, et al. The efficacy and safety of latanoprost 0.005% once daily versus brimonidine 0.2% twice daily in open-angle glaucoma or ocular hypertension. Am J Ophthalmol. 2001; 131:631-635.
15. Stewart WC, Day DG, Stewart JA, et al. Therapeutic success of latanoprost 0.005% compared to brimonidine 0.2% in patients with open-angle glaucoma or ocular hypertension. J Ocul Pharmacol Ther. 2000; 16:557-564.
16. Stewart WC, Sharpe ED, Day DG, et al. Comparison of the efficacy and safety of latanoprost 0.005% compared to brimonidine 0.2% or dorzolamide 2% when added to a topical beta-adrenergic blocker in patients with primary open-angle glaucoma or ocular hypertension. J Ocul Pharmacol Ther. 2000;16:251-259.
17. Simmons ST, Samuelson TW, for the Alphagan®/Xalatan® Study Group. Comparison of brimonidine with latanoprost in the adjunctive treatment of glaucoma. Clin Ther. 2000;22:388-399.
18. Simmons ST, Earl ML, for the Alphagan®/Xalatan® Study Group. Three-month comparison of brimonidine and latanoprost as adjunctive therapy in glaucoma and ocular hypertension patients uncontrolled on beta-blockers: tolerance and peak intraocular pressure lowering. Ophthalmology. 2002;109:307-314.
19. DuBiner HB, Mroz M, Shapiro AM, et al. A comparison of the efficacy and tolerability of brimonidine and latanoprost in adults with open-angle glaucoma or ocular hypertension: a three-month, multicenter, randomized, double-masked, parallel-group trial. Clin Ther. 2001;23:1969-1983.
20. Kampik A, Arias-Puente A, O'Brart D, et al. Intraocular pressure-lowering effects of latanoprost and brimonidine therapy in patients with open-angle glaucoma or ocular hypertension. A randomized, observer-masked multicenter study. J Glaucoma. 2002;11:90-96.
21. Thomas R, Parikh TR, Muliyil J, et al. Comparison between latanoprost and brimonidine efficacy and safety in Indian eyes. Indian J Ophthalmol. 2003;51:123-128.
22. Camras CB, Toris CB, Tamesis RR. Efficacy and adverse effects of medications used in the treatment of glaucoma. Drugs Aging. 1999;15: 377-388.
23. Camras CB, Minckler D. Does that drug work? Pitfalls in studies on the efficacy and safety of glaucoma medications. Am J Ophthalmol. 2000; 129:87-89.
24. Camras CB. Brimonidine and latanoprost as adjunctive therapy. Ophthalmology. 2003;110:6-8.
25. Crichton A, Drance SM, Douglas GR, et al. Unequal intraocular pressure and its relation to asymmetric visual field defects in low-tension glaucoma. Ophthalmology. 1989;96:1312-1314.
26. Haefliger IO, Hitchings RA. Relationship between asymmetry of visual field defects and intraocular pressure difference in an untreated normal (low) tension glaucoma population. Acta Ophthalmol Sound. 1990;68: 564-567.
27. Cartwright MJ, Anderson DR. Correlation of asymmetric damage with asymmetric intraocular pressure in normal-tension glaucoma (low-tension glaucoma). Arch Ophthalmol. 1988;106:898-900.
28. Leske MC, Heijl A, Hussein M, et al. Factors for glaucoma progression and the effect of treatment: the Early Manifest Glaucoma Trial. Arch Ophthalmol. 2003;212:48-56.
29. Derick RJ, Robin AL, Walters TR, et al. Brimonidine tartrate. A one-month dose response study. Ophthalmology. 1997;104:131-136.
30. Wax MB, Camras CB, Fiscella RG, et al. Emerging perspectives in glaucoma: optimizing 24-hour control of intraocular pressure. Am J Ophthalmol. 2002;133(Suppl):S1-S10.
31. Asrani S, Zeimer R, Wilensky J, et al. Large diurnal fluctuations in intraocular pressure are an independent risk factor in patients with glaucoma. J Glaucoma. 2000;9:134-142.